AbilityPharma abre ronda en Capital Cell de 1 millón de euros para seguir desarrollando un fármaco que elimina células cancerosas

by Ability Pharma

6 years ago
AbilityPharma, crowdfunding, ABTL0812, autofagia, cáncer

La compañía biotecnológica AbilityPharma acaba de lanzar una ronda de inversión de 1.000.000 de euros a través de la plataforma de crowdfunding Capital Cell para seguir desarrollando ABTL0812, un...

Ability Pharma announces FDA approval of phase 1/2 trial of ABTL0812 for patients with advanced metastatic pancreatic cancer

by Ability Pharma

6 years ago
ABTL0812, gemcitabine, nab-paclitaxel, metastatic pancreatic cancer

Ability Pharmaceuticals SL, a biopharmaceutical company announced today that the United States Food and Drug Administration (FDA) has approved a phase 1/2 study to assess the efficacy and safety of AB...

AbilityPharma announces FDA approval of IND for Phase 2 Trial of ABTL0812 in patients with endometrial cancer or squamous non-small cell lung cancer

by Ability Pharma

6 years ago
clinical trial, squamous non-small cell lung cancer, endometrial cancer, ABTL0812, PI3K/Akt/mTOR

Ability Pharmaceuticals SL, a biopharmaceutical company announced today that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application which vali...

Ability Pharmaceuticals anuncia la aprobación por parte de la Agencia Francesa de Medicamentos ANSM para iniciar el ensayo clínico de fase 1/2a con ABTL0812 para tratar pacientes con cáncer de endometrio o cáncer escamoso de pulmón como terapia de primera línea en Francia

by Ability Pharma

7 years ago
ABTL0812, ensayo clínico, cáncer de pulmón, cáncer de endometrio

ABTL0812 es una molécula contra el cáncer "first-in-class" totalmente diferenciado y administrado por vía oral, que inhibe la vía PI3K/Akt/mTOR sin ser un inhibidor directo de las quinasas. ABTL08...

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer

by Ability Pharma

7 years ago
orphan-drug designation, ABTL0812, pancreatic cancer

Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced today that has received orphan-drug designation (ODD) for ABTL0812 from the European Medicines ...

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer

by Ability Pharma

7 years ago
ODD, ABTL0812, Pancreatic Cancer, FDA-Orphan Drug Designation

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients

by Ability Pharma

8 years ago
ABTL0812, carboplatin, paclitaxel, cancer, lung, endometrial cancer

ABTL0812 is administered in combination with carboplatin and paclitaxel. Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Barcelona) lead...

Ability Pharmaceuticals enters into a licensing agreement with SciClone Pharmaceuticals for the novel anticancer agent ABTL0812 for the China market

by Ability Pharma

8 years ago
PI3K/Akt/mTOR, ABTL0812, lung cancer, endometrial cancer, SciClone Pharmaceuticals

Collaboration boosts development of a fully differentiated inhibitor of the PI3K/Akt/mTOR pathway. ABTL0812 is currently in Phase 2 clinical trials to treat lung and endometrial cancers.

Ability Pharmaceuticals announces positive Phase 1/1b study results of ABTL0812 in cancer patients with advanced solid tumors

by Ability Pharma

9 years ago
cancer, ABTL0812, drug development, advanced solid tumors

Study confirms that ABTL0812 is extremely well tolerated and shows promising signs of clinical antitumor activity. The results will be presented at AACR-NCI-EORTC International Conference on Molecular...

Ability Pharmaceuticals announces regulatory milestones for ABTL0812 in pediatric cancer neuroblastoma

by Ability Pharma

9 years ago
pediatric cancer, neuroblastoma, orphan-drug, ABTL0812, Food and Drug Administration

Ability Pharmaceuticals today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation (ODD) for ABTL0812, its PI3K/Akt/mTOR pathway inhibitor, for the ...